Opening question: When workshop, concert, and job-site videos sell “neuroprotective peptides” next to loud tools and speakers, do research-chemical catalogs replace the noise and hearing-protection basics CDC/NIOSH and OSHA still publish?
Short answer: no. Everyday hearing literacy still starts with recognizing hazardous noise, reducing exposure, and using effective hearing protection when needed—not with laboratory vials marketed as brain-shield shortcuts.
NIOSH and OSHA guidance on noise exposure
On its Understand Noise Exposure page, the National Institute for Occupational Safety and Health (NIOSH), part of CDC, states that workplace noise is hazardous with repeated exposures of 85 A-weighted decibels (dBA) or higher, and that hearing loss from noise is 100% preventable. The NIOSH recommended exposure limit (REL) for occupational noise is 85 dBA over an eight-hour shift. NIOSH notes that noise levels are likely hazardous if a person must raise their voice to speak with someone an arm’s length away, and that if workers are repeatedly exposed at or above the REL, employers must provide a hearing loss prevention program. The page also explains time-weighted averages, noise dose, sound-level meters and dosimeters, and annual audiometric testing recommendations for workers exposed above the REL.
OSHA’s Occupational Noise Exposure overview aligns on the practical threshold literacy: CDC estimates that 22 million workers are exposed to potentially damaging noise at work each year; exposure over 85 decibels can damage hearing; and if you need to raise your voice to speak to someone 3 feet away, levels might be over 85 dBA. OSHA requires a hearing conservation program when employee exposures equal or exceed 85 dBA as an 8-hour time-weighted average, and notes that engineering or administrative controls are required when exposure is above 90 dBA as an 8-hour TWA. OSHA states that noise-induced hearing loss is permanent and cannot be corrected with surgery or medicine, and that hearing protection devices are an acceptable but less desirable option than quieter machines, isolation, or limiting exposure time.
Semax evidence and FDA safety concerns
Alongside those basics, some catalogs market “neuroprotective peptides,” including Semax (an ACTH-fragment analogue), as if specialized brain-ischemia papers were hearing PPE. Filippenkov and colleagues’ Genes paper examines Semax (ACTH(4-7)PGP) transcriptome effects in a rat cerebral ischaemia–reperfusion (tMCAO) model and discusses neuroprotective framing in that experimental stroke context (PubMed 32580520). That is specialized animal-model molecular biology—not NIOSH noise control, and not a substitute for earmuffs, plugs, quieter equipment, or shorter exposure.
FDA’s public compounding materials further note that compounded drugs containing Semax (heptapeptide) may pose immunogenicity and impurity-characterization concerns and that the agency has no, or limited, safety-related information for proposed routes of administration. Research-only peptide listings are not FDA-approved neuroprotective medicines and are not interchangeable with OSHA/NIOSH hearing-loss prevention steps. For company facts only—not medical evidence—Apollo Peptides states that products are supplied for laboratory research only, are not for human or veterinary use, and describes third-party testing with certificates of analysis.
Practical literacy checklist (not medical advice):
- Does the ordinary noise plan still match NIOSH/OSHA—recognize ~85 dBA risk cues, prefer quieter controls, limit time near loud sources, and use correctly fitted hearing protection when needed?
- Is a cited “neuroprotective peptide” paper about specialized experimental brain ischemia rather than occupational or recreational noise exposure?
- Are “research-only” labels being confused with approved medicines or hearing PPE?
- Are ringing ears, temporary hearing change after noise, or workplace hearing concerns deferred to occupational health or a clinician rather than a catalog claim?
Bottom line: Hearing risk reduction still points first to NIOSH’s 85 dBA REL literacy and OSHA’s hearing-conservation framing. Semax has specialized experimental neuroprotection literature that does not equal consumer ear protection. Research-only peptide merchandise is a different category: laboratory-intended materials are not approved treatments, and company documentation is not clinical proof.
By The Everyday Brief · AI-assisted editorial. Drafted with AI research assistance; claims checked against opened NIOSH noise-exposure and OSHA noise pages, NCBI/PubMed abstract via E-utilities, FDA compounding safety-risk listing, and the company site on 2026-09-18 PT. No invented studies or quotes.
Sources
1. CDC/NIOSH — Understand Noise Exposure
2. OSHA — Occupational Noise Exposure
4. FDA — Certain Bulk Drug Substances That May Present Significant Safety Risks (incl. Semax)